Connect with us
European Gaming Congress 2024

Artificial Intelligence

Precision Medicine Market Size to Surpass USD 126.24 Billion by 2030 at 12.50% CAGR – Report by Market Research Future (MRFR)

Published

on

<!– Name:DistributionId Value:8840528 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1259337 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:5f9236a6-faf3-4dd5-badd-3f53cb30e000 –>

New York, USA, May 16, 2023 (GLOBE NEWSWIRE) — Precision Medicine Market Overview:

According to a Comprehensive Research Report by Market Research Future (MRFR), “Precision Medicine Market Information By Ecosystem Players, Sub-Markets, Therapeutics, and Region – Market Forecast by 2030”, the market size was valued at USD 49.2 billion in 2021 and is projected to grow from USD 55.35 Billion in 2022 to USD 126.24 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.50% during the forecast period (2022 – 2030).

Market Scope:

Precision medicine, sometimes referred to as “personalized medicine,” is a cutting-edge strategy for customizing illness prevention and treatment that considers variations in people’s genes, surroundings, and lifestyles.

Advertisement
Stake.com

Get Free Sample PDF Brochure @ https://www.marketresearchfuture.com/sample_request/925

Report Scope:

Report Attribute Details
Market Size in 2030 USD 126.24 Billion
CAGR 12.50%
Base Year 2021
Forecast Period 2022-2030
Historical Data 2020
Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered By Ecosystem Players, Sub-Markets and Therapeutics
Geographies Covered North America, Europe, Asia-Pacific, and Rest of the World (RoW)
Key Market Drivers Growing Prevalence of spine degeneration to boost the market growth
Increasing usage of Artificial intelligence in precision medicine is driving market growth.

Precision Medicine Market Competitive Outlook:

With significant industry changes including new product launches, mergers and acquisitions, contractual agreements, higher investments, and collaboration with other firms, market participants are also undertaking a variety of strategic activities to expand their global presence. Cost-effective products are a need for competitors in the precision medicine sector if they want to survive and flourish in a market that is becoming more and more competitive. Manufacturing locally to cut operational costs is one of the main business methods manufacturers use in the precision medicine industry to benefit customers and increase the market sector.

Key Companies in the Precision Medicine market include

Advertisement
Stake.com
  • Abbott Laboratories (USA)
  • Ab-Biotics Sa (USA)
  • Almac Group Ltd. (UK)
  • Asuragen Inc (USA)
  • Biobase Gmbh (Germany)
  • Biomérieux Sa(France)
  • Caris Life Sciences (USA)
  • Cepheid Inc. (USA)
  • Celtics Healthcare Technologies Gmbh (Germany)
  • GE Healthcare (USA)

Precision Medicine Market Trends:

Market Drivers

The primary market factors promoting market expansion include a rise in online collaborative forums, increasing attempts to describe genes, and developments in cancer biology. The rising need for innovative drugs to treat the rising prevalence of cancer and other diseases throughout the world is one reason contributing to the market’s expansion. Additionally, a lot of research partnerships with industry participants could benefit market expansion. Additionally, the use of AI in conjunction with technology developments is transforming the healthcare industry by enabling experts to capture and monitor clinical data more easily and with fewer mistakes. As a result, the market is expanding due to the growing use of artificial intelligence in precision medicine.

Additionally, advances in precision medicine have already led to important discoveries and therapies that have received FDA approval. These medicines, which have shown significant promise for the treatment of numerous diseases, are personalized to specific qualities of individuals, such as a person’s genetic composition or the genetic profile of a patient’s tumor. Patients with various malignancies often receive molecular testing as part of their treatment. Additionally, this enables medical professionals to choose treatments that raise patients’ chances of surviving cancer and decrease their likelihood of developing negative side effects. Because of this, the CAGR of the global market for precision medicine has increased in recent years.

Market Restraints

The market’s expansion is hampered by the high cost of diagnostic equipment and samples of precision medicine. Since companion diagnostics and genetic testing are required, precision medicine research and development is now more expensive than standard treatment. These factors so inhibit market expansion.

Advertisement
Stake.com

COVID-19 Analysis:

The market for precision medicine was impacted by the COVID-19 pandemic.  Precision medicine emphasizes more accurate diagnosis and treatment based on a variety of biomarkers, such as genetic variants and information about the environment, lifestyle, and behaviors of patients. These biomarkers are useful in identifying individual differences in susceptibility to and responses to COVID-19. Consequently, the COVID-19 pandemic caused a spike in interest in precision medicine. However, in the current environment, it is expected that the demand for precision medicine may continue to rise throughout the projected time due to the advent of more SARS-CoV-2 strains and the prevalence of other illnesses.

Browse In-depth Market Research Report (313 Pages) on Precision Medicine: https://www.marketresearchfuture.com/reports/precision-medicine-market-925

Precision Medicine Market Segmentation:

Ecosystem Players Insights

Advertisement
Stake.com

In terms of revenue, the pharmaceutical and biotechnology sector accounted for the lion’s share of the precision medicine market in 2021. Through early development and go-to-market strategies, precision medicine transforms the pharmaceutical value chain. In response to the demand from governmental organizations, regulators, and payers for “real-world evidence” of a drug’s efficacy and value for those stakeholders, pharmaceutical companies have developed personalized medicine, which is highly individualized.

Sub-Markets Insights

During the projection period, 2022–2030, the sector with the fastest-growing revenue is expected to be companion diagnostics, which led the market in 2021. This is a result of the creation of fresh biomarkers for several diseases as well as an increase in focused therapy research and development.

Therapeutics Insights

Throughout the projection period of 2022–2030, the cancer/oncology sector held the majority of market share in 2021. A fast expanding and promising research area called precision oncology allows for customized treatment based on a patient’s molecular and genetic makeup.

Advertisement
Stake.com

Buy Now: https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=925

Precision Medicine Market Regional Analysis:

The market for precision medicine in North America, which had a value of USD 21.25 billion in 2021, is anticipated to rise at a substantial CAGR throughout the research period. This is due to an increase in healthcare infrastructure investment, and financing for research and development (R&D) is anticipated to fuel the growth of the precision medicine industry in this area.

The second-largest market share for precision medicine is held by Europe, thanks to developments in areas like genome sequencing, diagnostic testing, and other areas. Improved technology and procedures are required by the personalized, individual approach to collect, store, and analyze information as well as contextualize, integrate, interpret, and offer prompt and accurate decision support in clinical and public health contexts. Additionally, the UK’s precision medicine market grew the quickest in the European area, while Germany’s precision medicine market had the biggest market share.

From 2022 to 2030, the market for precision medicine in Asia-Pacific is anticipated to expand at the quickest rate. This is because cutting-edge precision medicine can be tested in low-cost clinical trials, and because there have been significant financial expenditures in medical infrastructure and technology. Additionally, the India precision medicine market had the highest rate of growth in the Asia-Pacific region, while China’s precision medicine industry had the greatest market share.

Advertisement
Stake.com

Discover more research Reports on Healthcare Industry by Market Research Future:

Oncology Information Systems Market Research Report: Information By Product & Service Type (Software and Professional Services), By Application (Medical Oncology, Radiation Oncology and Surgical Oncology), By End User (Hospitals & Oncology Clinics, Government Institutes and Research Centers), and By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2030

Biomarker Tests Market Research Report Information By Application (Cancer, Cardiovascular, Infectious Diseases, Central Nervous Systems, and Others), By End User (Pharma & Biotech Companies, Diagnostic Tools Companies, Healthcare It/ Big Data Companies, and Clinical Laboratories), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2030

Companion Diagnostics Market Research Report Information by Product & Service (Assays, Kits, & Reagents and Software & Services), by Technology (Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), In Situ Hybridization (ISH), Immunohistochemistry (IHC), and Others), by Indication (Cancer [Lung Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Melanoma, and Others], Neurological Diseases, Infectious Diseases, Cardiovascular Diseases, and Others), by End User (Pharmaceutical & Biopharmaceutical Companies, Contract Research Organizations, Laboratories, and Others), and By Region (North America, Europe, Asia-Pacific, and Rest of the World) – Forecast till 2030

About Market Research Future:

Advertisement
Stake.com

Market Research Future (MRFR) is a global market research company that takes pride in its services, offering a complete and accurate analysis with regard to diverse markets and consumers worldwide. Market Research Future has the distinguished objective of providing the optimal quality research and granular research to clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help answer your most important questions.

Follow Us: LinkedIn | Twitter


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

ZA Tech Rebrands as Peak3, Raises US$35M Series A led by EQT

Published

on

za-tech-rebrands-as-peak3,-raises-us$35m-series-a-led-by-eqt

SINGAPORE, June 19, 2024 /PRNewswire/ — ZA Tech, the next-generation insurance core system SaaS provider, has rebranded as Peak3. With the successful completion of its US$35 million Series A fundraising from EQT (lead investor) and Alpha JWC Ventures, Peak3 now accelerates its expansion in the EMEA region and investments in complementary data and AI solutions.

In a market dominated by fragmented legacy technology, Peak3 has pioneered a cloud-native, modular insurance core and distribution system that combines comprehensive capabilities for life, health, and property and casualty (P&C) insurance. Since its founding in 2018, Peak3 has become a trusted technology partner to global insurers such as AIA, Generali, Prudential, and Zurich for their digital and traditional business. It has also partnered with leading digital platforms such as Carro, Grab, Klook, and PayPay to build and scale their embedded insurance businesses.
Besides the successful fundraising, Peak3 has recently achieved key milestones underpinning the rebranding. These transformative achievements include launching its first multi-country, multi-tenant core modernisation in Europe, rolling out an integrated customer data and big data platform for scaling analytics and AI capabilities, and establishing its first technology centre in Europe. The rebranding coincides with another major milestone: Issuing over a billion insurance policies on Peak3’s systems – including the first policies issued to North American customers and the first ones to be issued in Africa.
“We have evolved from an embedded insurance pioneer in Asia to a global end-to-end technology partner for the insurance industry,” said Bill Song, Peak3 Group CEO and Co-Founder. “Our new name represents three pinnacles: scaling the heights of innovation, surpassing performance limits, and delivering superior reliability – as we help insurers reach the highest summits of their cloud, data, and AI transformation.”
Bill Song also emphasised the growth opportunity: “There is an incredible tech investment backlog in the US$7-trillion global insurance industry. Continued digitalisation and the proliferation of AI will require structural investments by insurers over the next decade to modernise their core systems. We are uniquely positioned to capture this opportunity by providing the tech core foundations and innovation use cases.” 
To accelerate its growth journey, Peak3 completed its Series A fundraising and welcomed two new investors on its cap table: EQT, a major global technology investor with a deep heritage in Europe, and Alpha JWC Ventures, a leading venture firm in Southeast Asia. With the funding, Peak3 will advance its analytics and AI capabilities toward an intelligent core insurance solution, grow its EMEA operations and establish new system integrator partnerships. Peak3 targets double-digit ARR growth this year and is on the path to reach cashflow breakeven over the coming quarters.
“Peak3 has also proven its capability to deliver greenfield digital insurance initiatives and complex multi-country core modernisation projects in APAC and EMEA. As the lead investor, EQT is committed to empowering Peak3 in its go-to-market acceleration by leveraging our global network,” stated Clara Ho, Partner at EQT.
J.P. Morgan acted as exclusive financial advisor to Peak3 for this Series A fundraising.
For media inquiries and interview requests, please contact Carling Sia, Global Head of Branding and Marketing, at [email protected].
For more information on Peak3, please visit www.peak3.com. For more information on EQT, please visit www.eqtgroup.com.For more information on Alpha JWC Ventures, please visit www.alphajwc.com.
Photo – https://mma.prnewswire.com/media/2439599/Peak3_PR_Announcement_Photo__002.jpg

View original content:https://www.prnewswire.co.uk/news-releases/za-tech-rebrands-as-peak3-raises-us35m-series-a-led-by-eqt-302175431.html

Continue Reading

Artificial Intelligence

Lucinity Recognized as One of the Top 100 AI Fintech Companies Globally

Published

on

lucinity-recognized-as-one-of-the-top-100-ai-fintech-companies-globally

REYKJAVIK, Iceland, June 18, 2024 /PRNewswire/ — Lucinity has been featured in the AIFinTech100 list for 2024, marking its recognition as one of the top AI companies in the financial services industry. The AIFinTech100 list, curated by industry experts, highlights the most innovative fintech companies globally. Lucinity was selected from over 2,000 fintech firms for its problem-solving, market potential, innovation, and customer engagement. Earlier this year, Lucinity was also highlighted as a RegTech100 company.

 
 
This recognition comes amid rapid AI adoption in fintech. According to Fintech Global, research predicts the AI market in fintech will grow from $42.83 billion to $44.08 billion by 2024, reaching $50.87 billion by 2029. Banks alone are expected to spend $4.9 billion on AI platforms by 2024, with a 21.8% annual growth rate since 2019.
Lucinity’s inclusion in the AIFinTech100 list reflects its success in developing AI solutions that enhance efficiencies and cost savings for financial crime operations teams. Notably, Luci, the world’s first Generative AI copilot for financial crime investigations, launched in 2023, leverages Microsoft OpenAI technologies to augment human analysts’ capabilities, reducing investigation times from 3 hours to just 30 minutes. 
Lucinity also recently launched Luci as a copilot plugin at Money20/20. Financial institutions are now able to integrate Luci with any web-based enterprise application including CRM systems, Case Manager systems, and Excel, delivering immediate ROI with zero upfront integration. 
Security remains a significant challenge in AI adoption. Lucinity addresses this by partnering with Microsoft Azure develop a secure infrastructure. With a strong emphasis on compliance, Luci offers comprehensive auditability through its detailed Audit Log functionality.
Guðmundur Kristjánsson (GK), CEO of Lucinity, comments, “Being named in the AIFinTech100 showcases our impact amongst banks and fintech through advanced AI. It underscores our platform’s ability to empower compliance teams, deliver ROI, and reduce operational costs.”
Richard Sachar, Director of FinTech Global, added, “AI is revolutionizing financial services, increasing efficiencies and offering personalized products. This year’s AIFinTech100 list includes top innovators transforming the industry with AI applications.”
Lucinity’s inclusion in the AIFinTech100 list for 2024 follows several achievements, including winning the Microsoft Partner of the Year Awards for Sustainability and Social Impact and Partner of the Year – Iceland. Lucinity was also included in Chartis Research’s FinCrime and Compliance 50 Ranking for 2024 and was recognized as the best tool for Workflow Automation.
Name: Celina PabloEmail: [email protected] +354 792 4321
Logo – https://mma.prnewswire.com/media/2208676/4770157/Lucinity_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/lucinity-recognized-as-one-of-the-top-100-ai-fintech-companies-globally-302176061.html

Continue Reading

Artificial Intelligence

CRISIL wins Model Validation Tools and Accelerators category award, other recognitions from Chartis

Published

on

crisil-wins-model-validation-tools-and-accelerators-category-award,-other-recognitions-from-chartis

Recognized among top 50 financial services firms for analytics and risk tech
MUMBAI, India, June 18, 2024 /PRNewswire/ — CRISIL, a global provider of advanced analytics and risk management solutions, has won the Solution Category award for Model Validation Tools and Accelerators as part of the latest Chartis STORM 2024 report.

Published by Chartis Research, the leading provider of research and analysis on the global market for risk technology, STORM 2024 is an annual report on quantitative technologies and the computational infrastructure supporting it.
Following an extensive evaluation process, which included a risk technology survey, product demo, customer reference checks, and third-party sources of information, CRISIL won the following recognitions:
Solution category award for Model Validation Tools and AcceleratorsRanked Top 25 (#24) in QuantTech50 2024 rankingsRanked Top 25 (#24) in BuySideRisk50 2024 rankingsRanked Top 50 (#38) in RetailFinanceAnalytics50 2024 rankingsThe recognitions reflect the unparalleled value CRISIL brings to its clients through deep domain expertise, specialized analytical and technical knowledge and our global perspective.
Says Jan Larsen, President and Head, CRISIL Global Research & Risk Solutions, “CRISIL is honored by the recognition across multiple STORM50 award categories this year, including being named first place for Model Validation Tools and Accelerators. This is a great testament to the contributions of our team in giving clients and their regulators confidence in the models they use for making critical decisions.”
The core tenets of CRISIL’s value proposition include expertise across asset classes and risk stripes, analytical excellence and regulatory experience, tailored solutions focused on client delight, continuous improvement and technological innovation. 
Says Ashish Vora, President, CRISIL Market Intelligence and Analytics, “This prestigious recognition underscores the global acceptance of our risk management solutions and highlights our unwavering commitment to excellence in the risk technology space. Our Credit+ technology solutions have been instrumental in offering AI-enabled advanced analytics and driving efficiency, and we are particularly proud of the exceptional client feedback we have received for these solutions. We are constantly exploring new ways to enhance customer value and are investing in cutting-edge technology and domain expertise to maintain our position at the forefront of the industry.”
Notable examples of CRISIL’s platforms that help demonstrate this value proposition include: 
Model Infinity: A leading platform for model inventory management and model risk management. This innovative platform empowers our client to centralize all model activities, eliminates manual processes and operational risk, and provides a full audit trail of approvals for modeling assumptions and updates. Scenario Expansion Manager (SEM): A platform for clients to expand, analyze and track all regulatory and internal scenarios used for stress testing. As a centralized repository of scenarios, SEM allows institutions to eliminate redundant internal work and even provide clients the ability to share internal scenarios with one another. Credit+ ICON: The platform enables credit decision-making through its extensive financial spreading and front-end based credit risk scorecard hosting capabilities. Powered by deep domain expertise, AI-driven analytics and extensive configurability, it serves 40+ global clients across 15 countries.Credit+ Early Warning Signals: The AI-powered solution provides banks with actionable insights to monitor their credit quality, lower loan-loss contingencies and track corrective action plan.About CRISIL Market Intelligence & Analytics
About Global Research & Risk Solutions
About CRISIL Limited
Connect with us: LINKEDIN | TWITTER | YOUTUBE | FACEBOOK 
CRISIL PRIVACY
Disclaimer
This press release is transmitted to you for the sole purpose of dissemination through your newspaper/ magazine/ agency. The press release may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution of its press releases for consideration or otherwise through any media including websites, portals, etc.
CRISIL has taken due care and caution in preparing this press release. Information has been obtained by CRISIL from sources which it considers reliable. However, CRISIL does not guarantee the accuracy, adequacy or completeness of information on which this press release is based and is not responsible for any errors or omissions or for the results obtained from the use of this press release. CRISIL, especially states that it has no financial liability whatsoever to the subscribers/ users/ transmitters/ distributors of this press release.
Logo – https://mma.prnewswire.com/media/2211784/4276223/CRISIL_logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/crisil-wins-model-validation-tools-and-accelerators-category-award-other-recognitions-from-chartis-302175882.html

Continue Reading

Trending